New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma.Viktor Grünwald, Burghardt Wittig, Steffen Weikert et al.|Journal of Clinical Oncology|2012Cited by 1
Efficacy and safety of cancer vaccine with 4-fold gene-modified allogeneic tumor cells: Results of the phase I/II ASET study in patients with advanced renal cell carcinoma.Steffen Weikert, Burghardt Wittig, Matthias Schroff et al.|Journal of Clinical Oncology|2012Cited by 1
Abstract LB-233: Immune-related efficacy data of the phase 1-2 study of an with fourfold gene-modified allogeneic tumor cell based vaccine in patients with advanced renal cell carcinomaEkaterina Weith, Burghardt Wittig, Manuel Schmidt et al.|Cancer Research|2012Cited by 0